绿巨人视频污app

产物资料
  首页 >>> 产物目录 >>> **学 >>> 一抗

厂尘补诲3抗体

如果您对该产物感兴趣的话,可以
产物名称: 厂尘补诲3抗体
产物型号:
产物展商: XYbscience
产物文档: 无相关文档

简单介绍

厂尘补诲3抗体是一个蛋白家族的50 kDa成员,在细胞增殖、分化和发育过程中起重要作用。Smad家族分为三个亚类:受体调节Smads,激活素/β受体调节(Smad2、3)或BMP受体调节(Smad 1, 5、和8);普通合伙人(Smad4)功能,通过对各种Smads的相互作用;而抑制性蛋白,(Smad6和7)。厂尘补诲3抗体激活SMAD3齐聚与Smad4在TGF-β刺激和转移是一个复杂的成核,使其与DNA结合和转录因子。这两种TGF-β依赖的丝氨酸423和425在Smad3 C末端磷酸化是关键,Smad3转录活性的TGF-β信号。


厂尘补诲3抗体  的详细介绍
 

Smad3抗体ICC, IHC严格验证,品质保证.适用于多种种属反应性,被多篇文献引用并有用户反馈信息.确保特异性!产物具有以下特点:

1、全:网络全世界的上等产物,基本上各种抗体产物在该公司均能找到

2、新:产物及网站更新非常快,基本上每周均有新产物出现

3、优:产物质量好,投诉比较少

4、强:强大的技术支持队伍和力量,网站上有齐全的技术资料以及客户评论,并提供实时在线技术咨询,使您使用产物时没有任何后顾之忧。

产物编号xy-33222M

英文名称厂尘补诲3

中文名称细胞信号转导分子厂惭础顿3单克隆抗体

别    名hMAD 3; hSMAD3; HSPC193; JV15 2; JV152; MAD (mothers against decapentaplegic Drosophila) homolog 3; MAD3; MADH 3; MADH3; Mothers against decapentaplegic homolog 3; Mothers against DPP homolog 3; SMA and MAD related protein 3; SMAD 3; SMAD; SMAD-3; SMAD3_HUMAN.  

说 明 书50ul  100ul  

研究领域肿瘤  细胞生物  **学  信号转导  细胞凋亡  转录调节因子  

抗体来源惭辞耻蝉别

克隆类型惭辞苍辞肠濒辞苍补濒

克 隆 号10C4

Smad3抗体交叉反应 Human, Mouse, Rat,

产物应用IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:20-200 IF=1:100-500 (石蜡切片需做抗原修复)

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

分 子 量47kDa

细胞定位细胞核 细胞浆

性    状Lyophilized or Liquid

浓    度1mg/1ml

免 疫 原Recombinant human Smad3 Protein

亚    型IgG

纯化方法affinity purified by Protein G

储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

PubMedPubMed

产物介绍产补肠办驳谤辞耻苍诲:

Smad3 is a 50 kDa member of a family of proteins that act as key mediators of TGF beta superfamily signaling in cell proliferation, differentiation and development. The Smad family is divided into three subclasses: receptor regulated Smads, activin/TGF beta receptor regulated (Smad2 and 3) or BMP receptor regulated (Smad 1, 5, and 8); the common partner, (Smad4) that functions via its interaction to the various Smads; and the inhibitory Smads, (Smad6 and 7). Activated Smad3 oligomerizes with Smad4 upon TGF beta stimulation and translocates as a complex into the nucleus, allowing its binding to DNA and transcription factors. Phosphorylation of the two TGF beta dependent serines 423 and 425 in the C terminus of Smad3 is critical for Smad3 transcriptional activity and TGF beta signaling.


Function:

Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures (By similarity). Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.


Subunit:

Monomer; in the absence of TGF-beta. Homooligomer; in the presence of TGF-beta. Heterotrimer; forms a heterotrimer in the presence of TGF-beta consisting of two molecules of C-terminally phosphorylated SMAD2 or SMAD3 and one of SMAD4 to form the transcriptionally active SMAD2/SMAD3-SMAD4 complex. Interacts with TGFBR1. Part of a complex consisting of AIP1, ACVR2A, ACVR1B and SMAD3. Interacts with AIP1, TGFB1I1, TTRAP, FOXL2, PML, PRDM16, HGS and WWP1. Interacts (via MH2 domain) with CITED2 (via C-terminus) (By similarity). Interacts with NEDD4L; the interaction requires TGF-beta stimulation (By similarity). Interacts (via the MH2 domain) with ZFYVE9. Interacts with HDAC1, VDR, TGIF and TGIF2, RUNX3, CREBBP, SKOR1, SKOR2, SNON, ATF2, SMURF2 and TGFB1I1. Interacts with DACH1; the interaction inhibits the TGF-beta signaling. Forms a complex with SMAD2 and TRIM33 upon addition of TGF-beta. Found in a complex with SMAD3, RAN and XPO4. Interacts in the complex directly with XPO4. Interacts (via the MH2 domain) with LEMD3; the interaction represses SMAD3 transcriptional activity through preventing the formation of the heteromeric complex with SMAD4 and translocation to the nucleus. Interacts with RBPMS. Interacts (via MH2 domain) with MECOM. Interacts with WWTR1 (via its coiled-coil domain). Interacts (via the linker region) with EP300 (C-terminal); the interaction promotes SMAD3 acetylation and is enhanced by TGF-beta phosphorylation in the C-terminal of SMAD3. This interaction can be blocked by competitive binding of adenovirus oncoprotein E1A to the same C-terminal site on EP300, which then results in partially inhibited SMAD3/SMAD4 transcriptional activity. Interacts with SKI; the interaction represses SMAD3 transcriptional activity. Component of the multimeric complex SMAD3/SMAD4/JUN/FOS which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. Interacts (via an N-terminal domain) with JUN (via its basic DNA binding and leucine zipper domains); this interaction is essential for DNA binding and cooperative transcriptional activity in response to TGF-beta. Interacts with PPM1A; the interaction dephosphorylates SMAD3 in the C-terminal SXS motif leading to disruption of the SMAD2/3-SMAD4 complex, nuclear export and termination of TGF-beta signaling. Interacts (dephosphorylated form via the MH1 and MH2 domains) with RANBP3 (via its C-terminal R domain); the interaction results in the export of dephosphorylated SMAD3 out of the nucleus and termination of the TGF-beta signaling. Interacts with MEN1. Interacts with IL1F7. Interaction with CSNK1G2. Interacts with PDPK1 (via PH domain).


Subcellular Location:

Cytoplasm. Nucleus. Note=Cytoplasmic and nuclear in the absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus when complexed with SMAD4. Through the action of the phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported out of the nucleus by interaction with RANBP1. Co-localizes with LEMD3 at the nucleus inner membrane. MAPK-mediated phosphorylation appears to have no effect on nuclear import. PDPK1 prevents its nuclear translocation in response to TGF-beta.


Post-translational modifications:

Phosphorylated on serine and threonine residues. Enhanced phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on EGF AND TGF-beta treatment. Ser-208 is the main site of MAPK-mediated phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle dependent manner and inhibits both the transcriptional activity and antiproliferative functions of SMAD3. This phosphorylation is inhibited by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1 and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is required for interaction with SMAD4, nuclear location and transactivational activity, and appears to be a prerequisite for the TGF-beta mediated phosphorylation in the linker region. Dephosphorylated in the C-terminal SXS motif by PPM1A. This dephosphorylation disrupts the interaction with SMAD4, promotes nuclear export and terminates TGF-beta-mediated signaling. Phosphorylation at Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Phosphorylated by PDPK1.

Acetylation in the nucleus by EP300 in the MH2 domain regulates positively its transcriptional activity and is enhanced by TGF-beta.

Ubiquitinated.


DISEASE:

Defects in SMAD3 may be a cause of colorectal cancer (CRC) [MIM:114500].

Defects in SMAD3 are the cause of Loeys-Dietz syndrome type 1C (LDS1C) [MIM:613795]. LDS1C is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Patients with LDS1C also manifest early-onset osteoarthritis. They lack craniosynostosis and mental retardation.


Similarity:

Belongs to the dwarfin/SMAD family.

Contains 1 MH1 (MAD homology 1) domain.

Contains 1 MH2 (MAD homology 2) domain.


SWISS:

P84022


Gene ID:

4088

抗体选择指南

Smad3抗体检测任何目的靶蛋白都有不止一种抗体可供选择,为缩小抗体的选择范围选中合适的抗体,需要考虑如下几种因素:

1 分析或应用的类型

2)样本蛋白的结构性质

3)样本的种属

4)抗体宿主的种类

5)抗体的标记和检测

1 分析试验的应用类型一般抗体说明书都列出该抗体经试验验证过适用于何种分析类型,如:

可以应用于WB IHC ICC ELASA 分析等,如果抗体说明书没有提及的应用类型,并不意味着该抗体不适用于此种分析应用类型,而仅是说明尚未经过此种分析试验验证,如果抗体不适用某些分析试验,则会在抗体说明书上标注出来不适于某分析试验。

2 样本蛋白的结构性质了解样本蛋白的结构性质有助于选择*合适的抗体,至少需要考虑两方面因素

(1)..待测样本蛋白的结构域:Smad3抗体是由各种不同**原**宿主而制备得来,其中的**原包括:全长蛋白、蛋白片断、多肽、全有机体(如:**)或细胞,抗体说明书一般都有**原的描述,如果打算检测的是蛋白片断或一种特殊的同型物或蛋白全长的某一区域,则必须选择用含此片段域的**原制备出的抗体。如果打算用FACS 流式检测活细胞的表面蛋白,则需要选择含该表面蛋白的胞外域来**制备的抗体。

(2)样本的提取或处理过程:某些抗体要求样本经过某些特殊处理,例如:许多抗体只识别还原和变性的、表位已暴露不受二级四级结构阻碍的蛋白样本,另一方面,某些抗体仅识别天然折迭状态的蛋白。

当选择**组化的抗体时,应注意某些抗体只识别未固定的冷冻的组织,而另一些抗体则适用于无需抗原修复解交联步聚的甲醛固定石蜡包埋的组织,这些都会在抗体说明书上应用部分标示出来 3 样本的物种 应选择物种相同或有交叉反应的抗体,抗体可能与不同物种的同种靶蛋白有交叉反应,因其氨基酸序列同源性较高。

如果样本的种类未列入抗体说明书上的交叉反应种属表中,并不意味着该抗体不适用于检测该物种的蛋白,而只是表示该物种尚未用此抗体检测验证过,应通过序列比对的方法来预测交叉反应,Smad3抗体可应用Expasy NCBI BLAST 来进行不同物种蛋白同源性比对。

4 一抗宿主物种的选择一般说来,在使用偶联二抗结合无偶联物的一抗时,一抗宿主动物的物种选择较为重要,对于**组化而言,尽可能选择与样本不同种系物种的一抗,从而避免二抗与样本内源性**球蛋白产生交叉反应,

例如:检测小鼠样本蛋白,则不应选择小鼠或大鼠源的一抗,*好选兔源的一抗,则二抗则可选择偶联了检测分子(酶、荧光素、生物素等)的抗兔IgG。如果选择有偶联物的一抗则不适用上述情况,除**组化外的其它对不含内源性**球蛋白样本的检测方法,则抗体宿主物种的影响不大,如对不含IgG 的细胞裂解物样本的western blotting检测。

尽管如此,Smad3抗体含有血清的组织裂解物和组织培养上清中含有**球蛋白,还原变性样本中含IgG,在western blot 检测中则结合出现IgG 分子50 and 25 kDa 的重链和轻链条带。

5 二抗的选择 二抗应选用与使用的一抗相同的物种来源,例如:如果你的一抗是小鼠的单克隆抗体,二抗则选抗小鼠的二抗anti-mouse secondary。建议检查二抗说明书确保该抗体适用于你的检测应用, 二抗一般连接荧光素FITC 或发光团。

6 双重染色抗体的选择用未偶联一抗进行细胞培养物或组织切片的双重**染色要求一抗来源于不同物种并且二抗分别识别其中之一,二抗说明书应描述其与其它物种来源的**球蛋有否有交叉吸附。

合格 合格 Caveolin-1 细胞质膜微囊蛋白-1抗体
合格 phospho-EIF2S1 (Ser49) 磷酸化真核启动因子2α抗体
合格 eIF4A3 eIF4A3蛋白抗体
合格 phospho-eIF4EBP1(Thr70) 磷酸化eIF4E结合蛋白抗体
合格 phospho-EIF4B (Ser406) 磷酸化真核翻译起始因子4B抗体
合格 ELMO3 ELMO3蛋白抗体
合格 ELMOD1 ELMOD1蛋白抗体
合格 Adenosine Receptor A2a 腺苷A2A受体抗体
合格 合格 ELOV3 ELOV3蛋白抗体
合格 ELSPBP1 附睾精子结合蛋白1抗体
合格 EMG1 EMG1蛋白抗体
合格 Emi1 早期有丝分裂抑制蛋白1抗体
合格 EMR3 EMR3蛋白抗体
合格 合格 合格 LIFR 白血病抑制因子受体抗体
合格 ENDOD1 核酸内切酶结构域蛋白1抗体
合格 ENOX2 ENOX2蛋白抗体
合格 合格 CD130 白细胞介素6受体β/CD130抗体
合格 IL-23R 白介素-23受体抗体 
合格 EPM2AIP1 肌痉挛性癫痫病相互作用蛋白1抗体
合格 Epoxide hydrolase 1 环氧化物水解酶1抗体
合格 Eps8L3 EPS8相关蛋白3抗体
合格 ERGIC2 ERGIC2蛋白抗体
合格 Ermin Ermin蛋白抗体
合格 ERO1LB Ero1-Lβ蛋白抗体
合格 合格 ERp57 内质网蛋白57抗体
合格 ETS2.3 ETS2.3蛋白抗体

产物留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键础濒迟+厂或颁迟谤濒+贰苍迟别谤发送信息!
2.如有必要,请您留下您的详细联系方式!